Quillet-Mary A - Search Results

1

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions.

Boissard F, Tosolini M, Ligat L, Quillet-Mary A, Lopez F, Fournié JJ, Ysebaert L, Poupot M. Boissard F, et al. Oncotarget. 2016 Nov 26;8(32):52225-52236. doi: 10.18632/oncotarget.13660. eCollection 2017 Aug 8. Oncotarget. 2016. PMID: 28881725 Free PMC article.

2

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ. Gertner-Dardenne J, et al. Blood. 2009 May 14;113(20):4875-84. doi: 10.1182/blood-2008-08-172296. Epub 2009 Mar 10. Blood. 2009. PMID: 19278954 Free article.

3

Rituximab inhibits B-cell receptor signaling.

Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié JJ, Laurent G, Bezombes C. Kheirallah S, et al. Blood. 2010 Feb 4;115(5):985-94. doi: 10.1182/blood-2009-08-237537. Epub 2009 Nov 17. Blood. 2010. PMID: 19965664 Free article.

4

Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ. Capietto AH, et al. Curr Drug Targets. 2010 Jul;11(7):790-800. doi: 10.2174/138945010791320845. Curr Drug Targets. 2010. PMID: 20370648 Review.

5

Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A. Ysebaert L, et al. Leukemia. 2010 Jul;24(7):1310-6. doi: 10.1038/leu.2010.89. Epub 2010 May 13. Leukemia. 2010. PMID: 20463751

6

B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.

Gross E, L'Faqihi-Olive FE, Ysebaert L, Brassac M, Struski S, Kheirallah S, Fournié JJ, Laurent G, Quillet-Mary A. Gross E, et al. Leukemia. 2010 Nov;24(11):1885-92. doi: 10.1038/leu.2010.176. Epub 2010 Sep 9. Leukemia. 2010. PMID: 20827287

7

Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.

Liffraud C, Quillet-Mary A, Fournié JJ, Laurent G, Ysebaert L. Liffraud C, et al. Leuk Lymphoma. 2012 May;53(5):966-72. doi: 10.3109/10428194.2011.634041. Epub 2011 Dec 6. Leuk Lymphoma. 2012. PMID: 22023517

8

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Laprevotte E, Ysebaert L, Klein C, Valleron W, Blanc A, Gross E, Laurent G, Fournié JJ, Quillet-Mary A. Laprevotte E, et al. Leuk Res. 2013 Apr;37(4):440-6. doi: 10.1016/j.leukres.2012.11.015. Epub 2012 Dec 20. Leuk Res. 2013. PMID: 23259986

9

Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.

Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A. Laprevotte E, et al. J Immunol. 2013 Oct 1;191(7):3634-40. doi: 10.4049/jimmunol.1300187. Epub 2013 Aug 30. J Immunol. 2013. PMID: 23997218

10

Cancer stem cells of differentiated B-cell malignancies: models and consequences.

Gross E, Quillet-Mary A, Ysebaert L, Laurent G, Fournie JJ. Gross E, et al. Cancers (Basel). 2011 Mar 25;3(2):1566-79. doi: 10.3390/cancers3021566. Cancers (Basel). 2011. PMID: 24212774 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters